Valuation: Alector, Inc.

Market Cap 209M 184M 174M 158M 296M 20.04B 299M 2.09B 806M 10.23B 784M 767M 32.92B P/E 2026 *
-2.17x
P/E 2027 * -2.83x
Enterprise Value -18.67M -16.48M -15.59M -14.14M -26.51M -1.79B -26.77M -187M -72.07M -915M -70.11M -68.58M -2.94B EV / Sales 2026 *
-1.7x
EV / Sales 2027 * -3.14x
Free-Float
90.47%
Yield 2026 *
-
Yield 2027 * -
1 day-2.60%
1 week-6.97%
Current month-17.26%
1 month-20.09%
3 months-10.10%
6 months-6.50%
Current year+19.87%
1 week 1.86
Extreme 1.86
2.05
1 month 1.79
Extreme 1.79
2.76
Current year 1.37
Extreme 1.37
2.76
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
27
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 30/04/2013
Director of Finance/CFO 52 19/06/2025
Chief Tech/Sci/R&D Officer - 31/12/2016
Director TitleAgeSince
Director/Board Member 71 30/04/2013
Director/Board Member 72 30/09/2018
Chairman 77 12/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/26 Sell

Controller/Auditor

-3,625 0.0032%
03/09/26 Sell

Chief Financial Officer

-29,251 0.0262%
03/09/26 Sell

Founder

-72,606 0.0650%
Change 5-day change 1-year change 3-year change Capi.($)
-2.60%-6.97%-38.69%-71.14% 209M
-0.70%-4.28%+52.62%+86.42% 71.53B
+0.45%-0.82%+38.81%+84.19% 60.12B
+3.55%+5.11%+35.43%+24.86% 27.98B
-1.73%-4.30%-18.37%+357.94% 25.25B
-0.51%-2.28%+0.48%-9.27% 24.76B
+0.65%+1.67%+26.47%-7.62% 20.99B
+3.46%+3.02%+158.90%+337.81% 15.54B
+0.48%+0.86%+44.56%+168.42% 14.53B
+3.51%+1.41%-4.71%+523.16% 14.41B
Average +0.68%-1.41%+29.55%+149.48% 27.53B
Weighted average by Cap. +0.55%-1.52%+37.17%+130.06%

Financials

2026 *2027 *
Net sales 10.97M 9.68M 9.16M 8.31M 15.58M 1.05B 15.73M 110M 42.35M 538M 41.2M 40.3M 1.73B 28.01M 24.72M 23.39M 21.21M 39.76M 2.69B 40.16M 281M 108M 1.37B 105M 103M 4.42B
Net income -97.52M -86.06M -81.43M -73.84M -138M -9.36B -140M -977M -376M -4.78B -366M -358M -15.38B -97.35M -85.91M -81.28M -73.71M -138M -9.34B -140M -975M -376M -4.77B -366M -358M -15.35B
Net Debt -227M -201M -190M -172M -323M -21.83B -326M -2.28B -878M -11.15B -854M -836M -35.87B -297M -262M -248M -225M -421M -28.48B -425M -2.97B -1.15B -14.54B -1.11B -1.09B -46.79B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
29/09/26 US$1.870 -2.60% 960,739
28/09/26 US$1.920 -1.54% 713,343
25/09/26 US$1.950 +1.56% 1,024,565
24/09/26 US$1.920 -4.95% 849,547
23/09/26 US$2.020 +0.50% 1,182,749
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.870USD
Average target price
3.100USD
Spread / Average Target
+65.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock